CliffBio
small molecule

DORAL

QUAZEPAM

Loss of exclusivityJune 2028latest FDA-listed patent expiry
CompanyGalt Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameDORAL
Active ingredientQUAZEPAM
Strength15MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 1985
Marketing statusRX

Listed patents

PatentExpiresType
7608616June 2028use U-1012

More from Galt Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DORAL patent cliff — loss of exclusivity June 2028 | CliffBio